Track topics on Twitter Track topics that are important to you
Mylan NV executives have gotten up in front of investors every year and said they could bet on one thing -- that the maker of generic drugs would hit at least $6 in earnings per share in 2018. On Wednesday, Mylan cut its adjusted earnings forecast for next year to $5.40 a share, sending the shares tumbling.
Original Article: Generic Drug Price Slump's Latest Victim: Mylan's Profit TargetNEXT ARTICLE
A generic drug (generic drugs, short: generics) is a drug defined as "a drug product that is comparable to brand/reference listed drug product in dosage form, strength, route of administration, quality and performance characteristics, and intended u...